



ASX Announcement
15 August 2023

OPTISCAN ACHIEVES TELEPATHOLOGY MILESTONE

Optiscan Imaging Limited (ASX: OIL) is pleased to announce the completion of a key milestone in its telepathology project. The Company has been partnering with Canadian-based Prolucid Technologies to develop a high-performance telepathology platform that enables remote access for pathologists to undertake virtual biopsy assessments using Optiscan’s proprietary slide-free, biopsy-free, high resolution single cell imaging technology.

In collaboration with the world-leading Ontario-based Software as a Medical Device (SaMD) developer, the project has passed the proof of concept stage, achieving key milestones in de-risking elements such as software latency, data capacity and infrastructure composition ahead of schedule. Anticipated for completion by the end of 2024, the software will be 100% owned, managed, and commercialised by Optiscan, and will effectively position the Company at the forefront of real-time digital telepathology.

Optiscan CEO and Managing Director Dr Camile Farah, stated, “The current conventional histopathology or physical biopsy approach is time-consuming for health providers, uncomfortable for patients, and operationally challenging for anyone living in rural and remote areas. The combination of a high-performance, cloud-based telepathology platform integrated into our slide-free, biopsy-free single-cell imaging technology, presents a unique opportunity to establish a new standard of digital pathology across the world.”

“We are thrilled with the progress made with this exclusive collaboration with Optiscan,” said Darcy Bachert, Chief Executive Officer of Prolucid Technologies. “One of the challenges with SaMD solutions is identifying the appropriate infrastructure to build data-rich, commercially viable solutions. The scope and structure of Optiscan’s telepathology platform is technologically compatible, highly secure and quickly scalable across health systems. The key parameters and performance metrics for this SaMD are incredibly strong, and we are thrilled to be accelerating momentum in helping transform the pathology landscape with Optiscan.”

Dr Camile Farah, continued, “We believe our telepathology platform will mark a game-changing moment in digital pathology. The platform will bring significant value to patients residing in rural or remote settings, while granting health systems the ability to access pathology expertise from anywhere in the world from any location including the operating theatre for real-time consultations between surgeons and pathologists. We are immensely excited to be continuing this transformative journey and achieving our vision of making digital pathology for anyone, anywhere and anytime a reality.”

This announcement has been authorised for release by the Board of Optiscan.

– ends –

P: (61 3) 9538 3333

A: 16 Miles St, Mulgrave VIC 3170, Australia

W: www.optiscan.com

For investor queries, please contact:

Dr. Camile Farah

Chief Executive Officer & Managing Director – Optiscan Imaging Ltd

E: cfarah@optiscan.com

About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

P: (61 3) 9538 3333

A: 16 Miles St, Mulgrave VIC 3170, Australia

W: www.optiscan.com